EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
“Honestly, I’m quite alarmed by what we see in the U.S. now,” Novo Nordisk President and CEO Lars Fruergaard Jorgensen told CNN on Wednesday. “Patients who believe that they’re getting access to a ...
Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...
Novo Nordisk is working on a new obesity drug that could help patients shed more than any other weight-loss drug on the ...
U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and weight loss, according to a review of patient data published on Monday, the ...
Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...
Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...
Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.
Critics, including Senator Bernie Sanders, question whether the push to block alternatives is truly about safety — or simply ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback